Sportradar Group AG (SRAD) began trading on the Nasdaq on Tue 14 Sep 21

Sportradar Group AG, together with its subsidiaries, provides sports data services for the sports betting and media industries in the United Kingdom, the United States, Malta, Switzerland, and internationally.

• Sector(s): Technology
• Industry: Software—Application
• Full Time Employees: 2,959
• Incorporated in 2001
• HQ in St. Gallen, Switzerland
• https://www.sportradar.com 

Sportradar Group AG priceD 19 mln share IPO at $27.00 per share, in-line with the $25-28 expected range

VectivBio (VECT) began trading on the Nasdaq on Fri 9 Apr 21

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. 

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 42
• Incorporated in 2019
• Headquartered in Basel, Switzerland
• https://vectivbio.com

VectivBio priced 7.5 mln shares IPO at $17.00 per share, at the midpoint of the $16-18 expected range

ADC Therapeutics (ADCT) began trading on the NYSE on Fri 15 May 20

ADC Therapeutics prices upsized 12.45 mln share IPO at $19, above the $16-$18 expected price range

• The IPO was originally expected to consist of 10.3 mln shares.
• The lead underwriters on the deal were Morgan Stanley, BofA, and Cowen and Company.
• Ticker: ADCT

The funds will be used to complete a pivotal phase II trial of the company’s lead candidate Lonca in patients with the blood cancer diffuse large B-cell lymphoma, and ultimately bring the drug to the US market.

Lausanne-based ADC Therapeutics specializes in the development of antibody-drug conjugates, in which an antibody is attached to a chemotherapy drug. The antibody is designed to selectively bind to tumor cells, and once bound, the drug is internalized by the tumor where it releases its toxic effects. The specificity to the tumor means the treatment minimizes toxicity to healthy cells, reducing potential side-effects.

The company has a number of other candidates, targeting both blood cancers and solid tumors, in either the preclinical stage or early clinical trials. The funds raised from the IPO will also be used to further the development of these products.

Despite closing a €271M ($303M) Series E funding round in July 2019, adverse market conditions in October 2019 led ADC Therapeutics to withdraw its Nasdaq IPO.


The biotech’s IPO accompanies a €106M loan agreement made with the US firm Deerfield Management Company at the beginning of this month. Of the total loan, ADC Therapeutics can expect €60M upon completing its IPO, and another €46M once Lonca gets regulatory approval, amongst other conditions.  

Obseva (OBSV) began trading on Nasdaq on 26 Jan 17

ObsEva SA is a Swiss reproductive health and pregnancy therapeutics company.

• Geneva-based company, U.S. headquarters in Boston.
• Priced 6.45 million shares at $15 per share, within its previously-announced range of $14 to $16. 
• Raised $97 million in an initial public offering.

Credit Suisse Group AG reiterated an “outperform” rating and set a $27.00 target price on shares of Obseva SA in a report on Tuesday, April 18th. Leerink Swann initiated coverage on shares of Obseva SA in a report on Tuesday, February 21st. They issued an “outperform” rating and a $21.00 price objective on the stock. Finally, Jefferies Group LLC initiated coverage on shares of Obseva SA in a report on Tuesday, February 21st. They issued a “buy” rating and a $21.00 price objective on the stock.

Obseva SA last issued its quarterly earnings data on Thursday, May 18th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.17. Analysts forecast that Obseva SA will post ($2.11) EPS for the current fiscal year.

In the first half of 2017, ObsEva’s lead drug will enter two Phase 3 studies for the treatment of uterine fibroids, a kind of benign tumor, and will enter another Phase 3 trial in 2018 for the treatment of endometriosis, a disorder in which tissue that typically lines the uterus grows outside of the uterus.

The company is also developing a compound for in vitro fertilization, and recently completed a Phase 1 study of a drug to control preterm labor.